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ABSTRACT

INTRODUCTION

The Drug–Gene Interaction Database (DGIdb, www.
dgidb.org) is a web resource that consolidates disparate data sources describing drug–gene interactions and gene druggability. It provides an intuitive
graphical user interface and a documented application programming interface (API) for querying these
data. DGIdb was assembled through an extensive
manual curation effort, reflecting the combined information of twenty-seven sources. For DGIdb 2.0,
substantial updates have been made to increase
content and improve its usefulness as a resource
for mining clinically actionable drug targets. Specifically, nine new sources of drug–gene interactions
have been added, including seven resources specifically focused on interactions linked to clinical trials.
These additions have more than doubled the overall count of drug–gene interactions. The total number of druggable gene claims has also increased
by 30%. Importantly, a majority of the unrestricted,
publicly-accessible sources used in DGIdb are now
automatically updated on a weekly basis, providing
the most current information for these sources. Finally, a new web view and API have been developed
to allow searching for interactions by drug identifiers
to complement existing gene-based search functionality. With these updates, DGIdb represents a comprehensive and user friendly tool for mining the
druggable genome for precision medicine hypothesis generation.

With the increasing availability and decreasing cost of
molecular profiling methods, growing attention has been
paid to the use of these technologies for characterizing the
mechanisms of human disease at the cohort––and more recently, the individual––level (1–3). Improved understanding
of such molecular characteristics has been demonstrated
to impact the diagnostic, prognostic, and treatment decisions made by clinicians, yielding positive results, less toxicity and improved quality of life (4,5). However, finding
well-annotated drug–gene interactions relevant to medical
decision-making remains an ongoing challenge. Several resources exist that characterize both established and experimental drug–gene interactions but these resources vary
widely in data structure and complexity. Many of these
databases are missing useful features provided by DGIdb,
such as tools for querying lists of terms (6,7), filtering based
on interaction type (6–9) or gene class (7–9), and a RESTful API (7–10). Others lack a search interface entirely, and
instead have only a browsing interface (8) or are available
only as static supplementary documents published online
(11–20).
DGIdb 1.0 (21) was first introduced as a novel resource
to enable mining of multiple existing sources of drug–gene
interactions and druggable gene categories. drug–gene interactions are the observed or inferred interaction between
gene products (targets) and drug compounds (ligands) obtained by literature mining or by parsing publicly available
databases. Many of these interactions include information
on interaction types that specify how the drug interacts with
the gene. The curation of DGIdb sources for interaction
type data resulted in 33 distinct interaction type terms. In
simple cases, these terms were harmonized where the interaction types were unquestionably equivalent (e.g. ‘inhibitor’
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(8), TALC (18), and TEND (14), were primarily the result
of expert knowledge, or expert-driven curation of the literature. Due to their smaller size, these resources were more
closely vetted while imported into DGIdb, and thus the
‘expert-curated’ status also represents the focused curation
and literature review effort for these resources by the DGIdb
curators. In contrast, the ‘non-curated’ sources, such as GO
(26), PharmGKB (9), DrugBank (10) and TTD (7), are generally more inclusive of putative interactions and more comprehensive. For these reasons, these sources do not meet
the same standard of trust as the ‘expert-curated’ resources.
This is not intended to lessen the value of these excellent
resources. In fact, a notable amount of expert curation has
gone into each of the ‘non-curated’ resources, and has contributed greatly to the content included therein. The distinction made here is only in the specific context of therapyrelevant drug–gene interactions and/or druggability with a
bias toward cancer therapies, and is meant as a sorting tool
for our specific purposes. This coarse distinction may be
used by clinically-focused researchers to limit their search
to the ‘expert-curated’ category for higher standard results.
Despite its popularity, DGIdb 1.0 was limited in several
ways. The gene-centric search interface allowed the user to
find known drug interactions for a set of gene targets, but
did not provide a straightforward way of querying known
gene targets for a set of drugs. In addition, several popular
resources describing the druggable genome and drug–gene
interactions were missing from DGIdb. Finally, some of the
resources parsed by DGIdb are continually updated, creating a need for repeated manual updates to keep the associated data current.
With this update, we address these shortcomings. DGIdb
2.0 includes 14 new sources added since version 1.0 for a
cumulative total of 27 sources describing drug–gene interactions and druggable gene categories (Tables 1 and 2). These
include nine new expert-curated sources describing 10,102
drug–gene interactions potentially relevant to clinical actionability (e.g. relevant clinical trials, etc.). With this focus, DGIdb is better positioned as a resource for drug–gene
interaction hypothesis generation in precision medicine efforts. By reviewing drug–gene interactions that are clinically relevant, basic researchers and physician-scientists using DGIdb have a more useful reference for hypothesizing
which treatments might provide benefits for individual patients. Of special note are the addition of drug–gene interactions from the Clinical Interpretations of Variants in Cancer (CIViC, www.civicdb.org) database and the Database
of Curated Mutations (DoCM, www.docm.info), each of
which are a curated source of clinically relevant cancer
genes and their therapeutic interactions. DGIdb 2.0 also
contains three new sources of potentially druggable gene
category annotations, with 2,928 putatively druggable gene
category assignments between them (Figure 1). These additions enhance the existing capacity of DGIdb as a tool
for prioritizing development of new targeted therapies. Selected sources of gene, drug, interaction, and druggable categories are also now updated automatically, keeping DGIdb
current as more information is gathered and deposited in
the various sources aggregated by DGIdb. In addition to
content updates, DGIdb 2.0 also supports a major new
feature––searching interactions by drug identifier––which

Downloaded from http://nar.oxfordjournals.org/ at Washington University, Law School Library on November 10, 2015

= ‘inhibitors’). However, in most cases we felt it best to
preserve any subtleties of the interaction type according
to the source. Druggable gene categories include genes that
currently may not be targeted therapeutically but are potentially druggable according to their membership in gene
categories associated with druggability (e.g. kinases) (21).
These categories for the most part were defined by the original seminal paper by Hopkins and Groom (12) who first
defined the ‘druggable genome’ as genes belonging to over
130 specific biological types (kinases, nuclear hormone receptors, etc.) that were thought to be druggable, and our
curation of these types reduced that definition to 21 distinct
types that were incorporated into DGIdb. Russ and Lampel (16) published an update of the ‘Druggable Genome’
concept but without breaking down genes into specific categories. The dGene resource (13) was the most recent update
to the concept of a ‘Druggable Genome’ list. These lists,
while widely cited and used, were not available in any conveniently usable form. Therefore, we created a generic ‘Druggable Genome’ category, comprised of the union of these
three sources to act as a convenient label for these definitive
lists. Other categories from other sources are more specific.
The ‘Clinically Actionable’ category is a new concept with
the DGIdb 2.0 release describing lists of genes that are actively being used in targeted clinical sequencing panels for
precision medicine in cancer. The druggable gene categories
of DGIdb are by no means mutually exclusive, and in fact
often overlap extensively if not entirely (serine threonine kinases, for instance, are a subset of all kinases).
Populating DGIdb 1.0 was accomplished through an extensive curation effort. This process typically included manually extracting and reviewing records, converting them to
represent the concepts stored in the DGIdb, and writing
custom importers to load the data provided by each source.
Thirteen distinct sources were curated into a broad resource
that is simple to query and explore. Druggable gene categories could be browsed without any structured query, and
the interface accepted most common gene nomenclatures
as identifiers for searching drug–gene interactions. Data describing interactions or potentially druggable categories (referred to as interaction or category claims) from each of
these sources were linked to corresponding drug and gene
concepts. Each such source typically included important
metadata characterizing aspects of the interaction, such as
if a particular gene confers resistance or sensitivity to the
drug.
The breadth, quality, and ease-of-access enabled by this
resource is reflected in the substantial web traffic DGIdb
receives, with ∼1500 unique users and ∼2300 sessions a
month, with an average duration of ∼4.4 min/session.
In addition, a number of other bioinformatics tools have
used DGIdb in developing their own platforms including PANDA (22), iCAGES (icages.usc.edu), BioGPS (23),
OmicsPipe (24), GEMINI (25), StationX (www.stationxinc.
com) and IHLDB.rf (www.lungcancerdatabase.com), highlighting the broad usefulness of the DGIdb API. The first
version of DGIdb was released in October 2013, and has
since been cited in over 50 publications.
DGIdb 1.0 also provided a notion of ‘expert-curated’
and ‘non-curated’ resources as a search filter. ‘Expertcurated’ resources, such as dGene (13), MyCancerGenome
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allows users to find drug–gene interactions by querying the
database with drug identifiers in addition to gene identifiers.

these queries instead of exhaustively searching the numerous resources aggregated and curated by the DGIdb.

These additions improve the use of DGIdb as a tool
for precision medicine hypothesis generation. Clinical researchers that wish to make sense of lengthy gene lists may
use DGIdb to address numerous seemingly simple questions. One natural question is to ask if there is any information on interactions between drugs and their candidate
gene list. Alternatively one might ask if any of the genes
in that list belong to potentially druggable categories, such
as kinases, G-protein coupled receptors or transporters.
DGIdb provides an easy-to-use interface for seeking answers to these types of questions. In the process, DGIdb
handles the complexity of gene and drug name ambiguity,
provides informative results that detail what resources supplied the interaction or druggable gene category, and summarizes key metadata from each resource along with hyperlinks to the original drug and gene concepts (as applicable).
This reduces the burden of needing to search and decipher
the results of numerous resources (many of which are lists
from supplementary tables in papers or other static datastores). Using DGIdb, the clinical researcher may instead
focus their attention on reviewing the interesting results of

EXPANDED CONTENT
DGIdb 2.0 adds significantly to the existing content, providing a broader view of drug–gene interactions and potentially druggable genes from a large number of sources
(Figure 1). Most of this new content (89.5%) comes from
sources not present in DGIdb 1.0 and the remainder from
those original sources that have been updated with DGIdb
2.0. The top priority for new additions was that they describe high-quality, clinically actionable drug–gene interactions. First among these is the Clinical Interpretation of
Variants in Cancer (CIViC) web resource: an open-source,
community-driven site for the collaborative curation of clinically actionable variants in cancer. At time of last import,
CIViC contained 189 evidence statements from 112 published sources describing genes with variants that predict
sensitivity or resistance to specific drugs. In total 218 drug–
gene interactions were imported into DGIdb from these evidence statements. A second, similar resource, is the opensource Database of Curated Mutations (DoCM). Unlike
CIViC which is limited to mutations with proven clinical relevance, DoCM’s scope includes any highly curated variant
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Figure 1. DGIdb 1.0 and 2.0 content by source. Here, the number of genes with interactions (first panel), drug claims (second panel), drug–gene interaction
claims (third panel), and druggable gene categories (fourth panel) are contrasted between DGIdb 1.0 and 2.0. In total, there are currently 2,644 (33 new
to DGIdb 2.0) genes with interactions, 11,215 (1,023 new) drug claims, 40,017 (21,624 new) drug–gene interaction claims, and 18,500 (4,224 new) gene
category claims. Most of the new sources are considered to be high-quality, ‘expert-curated’ sources, and are indicated as such by the red triangle symbol.
Abbreviations: CF = Clearity Foundation, GTP = Guide To Pharmacology, MCG = My Cancer Genome, TALC = Targeted Agents in Lung Cancer,
TTD = Therapeutic Target Database, TEND = Trends in the Exploration of Novel Drug targets, and GO = Gene Ontology MSKCC = Memorial Sloan
Kettering Cancer Center.
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Table 1. Description of drug–gene interaction sources in DGIdb 2.0
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Table 2. Description of drug, gene and druggable gene category sources in DGIdb 2.0
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Beyond those added from the GTP, druggable gene category claims were added from four additional sources. The
Bader Laboratory (11) druggable gene category claims describe four protein families: Nuclear Hormone Receptors,
Kinases, Ion Channels, and Methyltransferases, long considered to be druggable (16). Prior to import into DGIdb,
these claims were only available online as supplementary
tables (11). The Foundation One (19) diagnostic test focuses on clinically actionable genes, and DGIdb 2.0 uses
the data from this source as a new ‘clinically actionable’ druggable gene category. As with the Bader Lab resource, these genes were obtained from an online table
on their website (foundationone.com/genelist1.php). The
‘Clinically Actionable’ gene category also had additions
from cancer-focused genetic testing panels from Memorial
Sloan Kettering (20) and Caris Life Sciences (http://www.
carismolecularintelligence.com/profilemenu).
With the content from these new sources, there is an
abundance of clinical evidence data to support drug–
gene interaction queries. Currently, DGIdb contains 26,298
unique drug–gene interaction claims involving 2,644 genes
and 7,569 drugs, and 7,524 unique genes belonging to one
or more of 41 potentially druggable gene categories. A total of 8,419 unique genes either have known or potential
druggability. We are still far from completely illuminating
the ‘dark matter’ of the druggable genome (Isserlin et al.,
http://arxiv.org/abs/1102.0448); of the genes in potentially
druggable gene categories, only 26.4% (1,983) actually have
a known drug–gene interaction (Supplementary Figure S1).
Moreover, it is likely that only a fraction of these represent effective targeted therapies. Conversely, only 75.0%
(1,983/2,644) of unique genes with at least one drug–gene
interaction belong to an existing druggable gene category.
The latter illustrates our potentially still inadequate definition of the ‘druggable genome’, but does represent a modest improvement over the 65.2% (1,704/2,611) coverage observed in DGIdb 1.0.
To demonstrate an application of the expanded content
of DGIdb 2.0, we evaluated pan-cancer data from The Cancer Genome Atlas (TCGA) (29), and used the R package
GenVisR (https://github.com/griffithlab/GenVisR) to illustrate the potential druggability of highly recurrent mutated
genes in this cohort (Figure 2A). Of the top 62 recurrently
mutated genes (those mutated in at least 5% of the evaluated tumors), 16 have known drug–gene interactions in
DGIdb 2.0. Moreover, multiple drugs are available for 14 of
these. This is a notable improvement from DGIdb 1.0, with
nearly a three-fold (193.6%) overall increase in the number
of drug–gene interactions for this set. A search of the top
488 recurrently mutated genes (those genes mutated in at
least 2.5% of the evaluated tumors) shows that 137 genes
(28%) are present in at least one potentially druggable gene
category (Figure 2B). Of these, 57 genes (42%) have known
drug–gene interactions, and 30 genes (22%) have drug–gene
interactions that are based on data describing clinical evidence. These results demonstrate the usefulness of DGIdb
as a tool to explore potential hypotheses for clinically actionable drug interactions with implicated cancer genes.
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with a demonstrated role in cancer etiology. A key dataset
included in DoCM is the collected annotations of clinically
actionable mutations as reported by the Gene Drug Knowledge Database (27).
In addition to CIViC and DoCM, six other notable, curated sources of clinical evidence-based drug–gene interactions were integrated in the DGIdb 2.0 release. RaskAndersen et al. (15) released a carefully curated list of
putatively novel clinical trial drug targets, based upon
mining CenterWatch’s Drugs in Clinical Trials Database
(centerwatch.com). Their list of clinical drug–gene interactions is available as a supplementary table in their publication, and was imported into the DGIdb as the ‘Druggable Genome: Clinical Trials’ (‘TdgClinicalTrials’) resource (5,998 claims). My Cancer Genome (MCG) (8) is
an original resource included in DGIdb 1.0 (21). However, since the DGIdb 1.0 release, a My Cancer Genome
clinical trials search function was introduced. This search
tool was used to manually collect information for any clinical trials involving drug–gene interactions. The results were
recorded in a table and subsequently imported into DGIdb
(1913 claims). Unfortunately, this search functionality is
no longer available on the My Cancer Genome site. The
Clearity Foundation (clearityfoundation.org) works with
patients with ovarian cancer to identify therapeutic strategies guided by biomarkers. To support this effort they have
created a database of actionable biomarkers through analysis of thousands of patient tumors. These biomarkers, and
their effect on drug sensitivity, constitute drug–gene interactions. With permission from Clearity Foundation, these
interactions were extracted from their website and imported
into DGIdb (165 claims). In addition, Clearity provided
us with 124 manually curated clinical trial records with at
least one drug–gene interaction for review and import into
DGIdb as the Clearity Foundation Clinical Trial resource
(585 claims). DGIdb also includes drug–gene interactions
from Cancer Commons (cancercommons.org), a group that
formerly enrolled patients with lung cancer, skin cancer, and
prostate cancer to profile their tumors and help connect
patient tumor profiles with potential therapies, in a selfdescribed ‘macro-scale N-of-1 adaptive trial’. This group
curated clinical trial records for genes targeted by FDA approved drugs in these three diseases. The resulting lists of
drug–gene interactions, annotated with existing or ongoing
collection of clinical data, are available online as HTML
tables, and were extracted for import into DGIdb. Finally,
DGIdb now includes 1,192 high-quality drug–gene interactions involving FDA approved drugs with single gene targets from the ChEMBL 20 database (28).
The largest source of new content was imported from
the IUPHAR/BPS Guide To Pharmacology (GTP) (6), accounting for 10 225 interaction claims and 1,969 druggable
gene category claims. GTP includes a detailed arrangement
of both genes (targets) and compounds (ligands) into functional categories. GTP is the only resource added in DGIdb
2.0 that is considered ‘non-curated’, as the results of DGIdb
queries of GTP more closely resemble the specificity of
other large resources such as DrugBank. GTP also provides
groupings of gene targets into families, which we mapped to
existing druggable gene categories through an extensive curation effort (Supplementary Methods).

6 Nucleic Acids Research, 2015

Downloaded from http://nar.oxfordjournals.org/ at Washington University, Law School Library on November 10, 2015

Figure 2. DGIdb analysis of TCGA pan cancer recurrently mutated genes. (A) The 62 genes recurrently mutated in at least 5% of pan-cancer tumors, and
the corresponding mutations observed in each tumor. (B) The number of potentially druggable genes among the 488 genes recurrently mutated in at least
2.5% of tumors, grouped by druggable gene categories. Colored bars indicate the fraction of each such category with interactions in a clinical evidence
source, a non-clinical evidence source, or without interactions. GPCR = G-Protein Coupled Receptor, PI-3K = Phosphatidylinositol 3 Kinase, ST Kinase
= Serine Threonine Kinase
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Figure 3. The drug search interface. (A) Switching between gene and drug searches is as simple as selecting the mode with this button. (B) A search field that
accepts a variety of drug or gene identifiers, and provides autocompletion suggestions for terms in the database. (C) Filters allow search results to be limited
by the source database, curation level, and interaction type. (D) Users may select to review the results summary or more detailed views. (E) The results
summary links genes and drugs by interaction and shows which of the queried resources contain interaction data. (F) The unique sources and PMIDs
associated with each interaction are displayed to the user. These are combined to provide a score value that may be used for ranking the interactions.

8 Nucleic Acids Research, 2015

NEW FUNCTIONALITY

CONCLUSION AND FUTURE DIRECTIONS
DGIdb 2.0 has greatly expanded in content for both drug–
gene interactions and druggable gene categories. The numerous sources describing clinical evidence of drug–gene
interactions have created a useful resource for reviewing the
nature of these interactions in a clinical setting. These additions have been made with the express purpose of improving
DGIdb for use in clinically relevant applications. DGIdb remains a powerful tool for web-based searches, and also as
an add-on service for clinical informatics pipelines through
the well-documented API. This aspect of DGIdb has been
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Drug-based search is a new and often-requested feature introduced in DGIdb 2.0, and is a major improvement to the
existing search capabilities. DGIdb 1.0 provided a search
form for entering mixed gene identifiers (IDs) including
gene symbols, Entrez IDs, UniProt symbols, etc., to get
a list of drug–gene interactions (Figure 3A). We have expanded the functionality of this form to alternatively use
drug IDs for the search process (Figure 3B). These may take
the form of any of the varied IDs in the database, including PubChem Compound and Substance IDs, Drugbank
IDs, common drug names, brand names, CAS numbers,
etc. The drug search results work in much the same way as
the gene search results (21). Drug terms are first matched
against PubChem primary names, then against any other
identifiers. If an exact match is found to a DGIdb drug,
DGIdb searches for drug–gene interactions involving that
drug. Filters allow the search space to be constrained by
source, interaction type, trust level or gene category (Figure 3C). If any search terms are ambiguous (i.e. the search
term matches more than one drug concept) or no matches
are found, this information is summarized in the ‘Search
Term Summary’ tab and in detail in the ‘Detailed Results’
tab (Figure 3D). On the default ‘Search Term Summary’
tab, interactions are grouped together and the sources supporting each interaction are indicated (Figure 3E). Finally,
an indication of the number of distinct sources and distinct
PubMed IDs (PMIDs) supporting each interaction are provided, along with a score that accounts for both of these values. The results are sortable by inclusion in any particular
database or by the described metrics (Figure 3F).
Finally, DGIdb 2.0 now features a codebase supporting
the automatic update from sources for each of the core concepts in DGIdb: genes, drugs, drug–gene interactions and
druggable gene categories. These updaters have been built
for the most actively updated existing sources (Figure 1), including DrugBank (10) (drug–gene interactions), Gene Ontology (26) (druggable gene categories), Entrez (30) (genes),
and PubChem (31) (drugs). For sources updated from version 1.0 to 2.0, the smallest increase we observed was for
PubChem, at 1,023 additional drugs (10%). The largest increase was for Entrez Gene, which increased by 13,348 genes
(31%), and precisely reflects the corresponding increase in
gene identifiers as reported by Entrez (Supplementary Figure S2). These large changes highlight the importance of a
continually updated resource, particularly for resources that
are applicable to precision medicine hypothesis generation.

improved with the addition of drug-based searches of drug–
gene interactions, enhancing the facility with which DGIdb
can mine the druggable genome. Automated content updates for large, regularly updated sources now ensures that
DGIdb 2.0 will provide users with the most current knowledge of clinically actionable drug–gene interactions.
As DGIdb continues to grow, we anticipate additional
improvements to accommodate the complexity of representing drug–gene interactions and druggable gene category
assignments. A future goal is to better represent many-toone relationships between genes and drugs for interactions.
This would include both multi-drug interactions with individual gene targets, and drugs that simultaneously interact
with multiple genes. These types of data will become increasingly available for aggregation and representation as
clinical data describing these events are entered as evidence
in resources such as CIViC. We also plan a corresponding
expansion of our API, adding options for queries that take
advantage of these new data relationships. We also wish to
study a more sophisticated scoring and ranking system that
takes into account other metrics, such as source quality and
FDA drug information. Additionally, we plan to investigate
better strategies for the grouping of related drug concepts.
Finally, we plan to continue adding new sources of drug–
gene interactions as identified by our group or suggested
by users of the resource. Several features and sources of the
DGIdb were developed through feedback from this community, for which we express our gratitude.

Nucleic Acids Research, 2015 9

21.

22.

23.

24.

25.
26.
27.

28.

29.

30.

31.
32.

capture-based next-generation sequencing clinical assay for solid
tumor molecular oncology. J. Mol. Diagn., 17, 251–264.
Griffith,M., Griffith,O.L., Coffman,A.C., Weible,J.V.,
McMichael,J.F., Spies,N.C., Koval,J., Das,I., Callaway,M.B.,
Eldred,J.M. et al. (2013) DGIdb: mining the druggable genome. Nat.
Methods, 10, 1209–1210.
Hart,S.N., Moore,R.M., Zimmermann,M.T., Oliver,G.R., Egan,J.B.,
Bryce,A.H. and Kocher,J.P. (2015) PANDA: pathway and
annotation explorer for visualizing and interpreting gene-centric
data. PeerJ, 3, e970.
Wu,C., Orozco,C., Boyer,J., Leglise,M., Goodale,J., Batalov,S.,
Hodge,C.L., Haase,J., Janes,J., Huss,J.W.3rd et al. (2009) BioGPS:
an extensible and customizable portal for querying and organizing
gene annotation resources. Genome Biol., 10, R130.
Fisch,K.M., Meissner,T., Gioia,L., Ducom,J.C., Carland,T.M.,
Loguercio,S. and Su,A.I. (2015) Omics Pipe: a community-based
framework for reproducible multi-omics data analysis.
Bioinformatics, 31, 1724–1728.
Paila,U., Chapman,B.A., Kirchner,R. and Quinlan,A.R. (2013)
GEMINI: integrative exploration of genetic variation and genome
annotations. PLoS Comput. Biol., 9, e1003153.
Gene Ontology, C. (2015) Gene Ontology Consortium: going
forward. Nucleic Acids Res., 43, D1049–D1056.
Dienstmann,R., Dong,F., Borger,D., Dias-Santagata,D.,
Ellisen,L.W., Le,L.P. and Iafrate,A.J. (2014) Standardized decision
support in next generation sequencing reports of somatic cancer
variants. Mol. Oncol., 8, 859–873.
Bento,A.P., Gaulton,A., Hersey,A., Bellis,L.J., Chambers,J.,
Davies,M., Kruger,F.A., Light,Y., Mak,L., McGlinchey,S. et al.
(2014) The ChEMBL bioactivity database: an update. Nucleic Acids
Res., 42, D1083–1090.
Kandoth,C., McLellan,M.D., Vandin,F., Ye,K., Niu,B., Lu,C.,
Xie,M., Zhang,Q., McMichael,J.F., Wyczalkowski,M.A. et al. (2013)
Mutational landscape and significance across 12 major cancer types.
Nature, 502, 333–339.
Brown,G.R., Hem,V., Katz,K.S., Ovetsky,M., Wallin,C.,
Ermolaeva,O., Tolstoy,I., Tatusova,T., Pruitt,K.D., Maglott,D.R.
et al. (2015) Gene: a gene-centered information resource at NCBI.
Nucleic Acids Res., 43, D36–D42.
Bolton,E.E., Wang,Y., Thiessen,P.A. and Bryant,S.H. (2008)
PubChem: integrated platform of small molecules and biological
activities. Annu. Rep. Comput. Chem., 4, 217–241.
Cunningham,F., Amode,M., Barrell,D., Beal,K. et al.
(2015) Ensembl 2015. Nucleic Acids Res, 43, D662–D669.

Downloaded from http://nar.oxfordjournals.org/ at Washington University, Law School Library on November 10, 2015

8. Yeh,P., Chen,H., Andrews,J., Naser,R., Pao,W. and Horn,L. (2013)
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment
(DIRECT): a catalog of clinically relevant cancer mutations to
enable genome-directed anticancer therapy. Clin. Cancer Res., 19,
1894–1901.
9. McDonagh,E.M., Whirl-Carrillo,M., Garten,Y., Altman,R.B. and
Klein,T.E. (2011) From pharmacogenomic knowledge acquisition to
clinical applications: the PharmGKB as a clinical pharmacogenomic
biomarker resource. Biomark Med., 5, 795–806.
10. Law,V., Knox,C., Djoumbou,Y., Jewison,T., Guo,A.C., Liu,Y.,
Maciejewski,A., Arndt,D., Wilson,M., Neveu,V. et al. (2014)
DrugBank 4.0: shedding new light on drug metabolism. Nucleic
Acids Res., 42, D1091–1097.
11. Edwards,A.M., Isserlin,R., Bader,G.D., Frye,S.V., Willson,T.M. and
Yu,F.H. (2011) Too many roads not taken. Nature, 470, 163–165.
12. Hopkins,A.L. and Groom,C.R. (2002) The druggable genome. Nat.
Rev. Drug Discov., 1, 727–730.
13. Kumar,R.D., Chang,L.W., Ellis,M.J. and Bose,R. (2013) Prioritizing
potentially druggable mutations with dGene: an annotation tool for
cancer genome sequencing data. PLoS One, 8, e67980.
14. Rask-Andersen,M., Almen,M.S. and Schioth,H.B. (2011) Trends in
the exploitation of novel drug targets. Nat. Rev. Drug Discov., 10,
579–590.
15. Rask-Andersen,M., Masuram,S. and Schioth,H.B. (2014) The
druggable genome: evaluation of drug targets in clinical trials
suggests major shifts in molecular class and indication. Annu. Rev.
Pharmacol. Toxicol., 54, 9–26.
16. Russ,A.P. and Lampel,S. (2005) The druggable genome: an update.
Drug Discov. Today, 10, 1607–1610.
17. Shrager,J., Tenenbaum,J.M. and Travers,M. (2011) Cancer
commons: biomedicine in the internet age. Collab. Comput. Technol.
Biomed. Res., 161–177.
18. Somaiah,N., Simon,N.G. and Simon,G.R. (2012) A tabulated
summary of targeted and biologic therapies for non-small-cell lung
cancer. J. Thorac. Oncol., 7, S342–368.
19. Wagle,N., Berger,M.F., Davis,M.J., Blumenstiel,B., Defelice,M.,
Pochanard,P., Ducar,M., Van Hummelen,P., Macconaill,L.E.,
Hahn,W.C. et al. (2012) High-throughput detection of actionable
genomic alterations in clinical tumor samples by targeted, massively
parallel sequencing. Cancer Discov., 2, 82–93.
20. Cheng,D.T., Mitchell,T.N., Zehir,A., Shah,R.H., Benayed,R.,
Syed,A., Chandramohan,R., Liu,Z.Y., Won,H.H., Scott,S.N. et al.
(2015) Memorial sloan kettering-integrated mutation profiling of
actionable cancer targets (MSK-IMPACT): a hybridization

